remlifanserin

all catalysts(0)

nothing on the calendar yet

News(3)

• Novo pursues long-acting obesity drugs; Acadia slumps on Alzheimer’s data
  Novo’s latest alliance involves injectables given every one to three months. Elsewhere, Nektar won a legal spat with Eli Lilly and the FDA issued two approvals.
  biopharma_dive · 8d ago
• Acadia slides on Phase 2 miss in Alzheimer’s psychosis but keeps moving asset forward
  While Acadia Pharmaceuticals’ candidate has missed the main goal of a Phase 2 trial, the company is still moving forward with the anti-psychosis candidate in Alzheimer’s disease as well as Lewy bod…
  biospace · 9d ago
• Acadia misses mark in Alzheimer’s but concludes phase 3 ‘absolutely worth’ pursuing
  Acadia Pharmaceuticals’ phase 2 Alzheimer’s disease trial has missed its primary endpoint, but the company and analysts alike saw enough encouraging signals to support the continuation of a phase 3…
  fiercebiotech · 9d ago